Data-Gouv-ML/pcri-informations-sur-les-projets-laureats huggingface dataset:
Atrial Fibrillation, Fibrosis and Rotors: New Insights from Imaging and Computational Modeling (AFIBROTIC)

Framework: Horizon 2020 — Excellent Science
Programme: Marie-Sklodowska-Curie Actions
Theme: Marie Skłodowska-Curie
Destination: Individual Fellowships (IF)-Standard European Fellowships
Action type: Marie Skłodowska-Curie actions
Panel: Information Science and Engineering
Countries involved: Italy
Call: Marie Skłodowska-Curie Individual Fellowships (IF-EF) (H2020-MSCA-IF-2014, 2014)
Start date: 2015-10-01
End date: 2017-09-30
Duration (months): 24.0
Total project cost (EUR): 168277.2
EU funding (EUR): 168277.2
Participants: 1
Project status: CLOSED

Atrial fibrillation (AF) is the most common type of arrhythmia and causes substantial morbidity and mortality. AF is principally treated with catheter ablation. Unfortunately, the mechanisms that initiate and sustain the arrhythmia are still incompletely understood and, as such, ablation remains a highly operator-dependent procedure with low success rates. Two recent studies promise to lead to better ablation outcomes, showing that a) the amount of atrial fibrosis directly correlates with the non-responsiveness to ablation and that b) AF is maintained by electrical rotors and targeting their suppression improves the success rates. Nonetheless, the lack of a rigorous mechanistic framework of AF pathophysiology deprives those studies of solid fundaments so that their effective value is still debated. This project aims therefore to provide such a framework by exploiting advanced biomedical engineering concepts. The focus will be on explaining and connecting recent experimental findings about fibrosis and rotors. The relationship will be first analyzed in vivo from AF patient data acquired with state-of-the-art instrumentation in the field of interventional electrophysiology. Measured data will be then integrated within a multi-scale personalized computational model of the fibrillating atrium that will determine, on a patient-specific basis, the mechanistic connection between fibrosis and reentries. Furthermore, the tool will provide an in silico environment for personalized ablation planning. Key in the project will be the synergy between complementary state-of-the-art expertise in the fields of medical imaging and computational modeling provided by applicant and host institutions. All partners will strongly benefit from the implied two way knowledge transfer, in terms of career advancement (the applicant) and enlarged network/grant proposal opportunities. The study will foster more focused clinical research aiming at better treatment for the AF patients.

Keywords: atrial fibrillation,catheter ablation,procedure planning,computational modeling,patient specific,in silico medicine,fibrosis,reentrant circuits
Structural and mechanistic insights into RING E3-mediated ubiquitination (RINGE3)

Framework: Horizon 2020 — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Consolidator grants
Action type: ERC actions
Panel: Molecules of Life: Biological Mechanisms, Structures and Functions
Panel description: Molecular biology, biochemistry, structural biology, molecular biophysics, synthetic and chemical biology, drug design, innovative methods and modelling
Countries involved: United Kingdom
Call: ERC Consolidator Grant (ERC-2014-CoG, 2014)
Start date: 2015-05-01
End date: 2020-04-30
Duration (months): 60.0
Total project cost (EUR): 2000000.0
EU funding (EUR): 2000000.0
Participants: 1
Project status: CLOSED

Ubiquitin (Ub) conjugation regulates a myriad of cellular processes in the eukaryotic cell. Ub-ligases (E3) play a pivotal role in deciding the substrate’s fate and function by catalyzing the transfer of Ub from Ub-conjugating enzyme (E2) to a substrate protein lysine sidechain. Successive rounds of E3-catalyzed substrate ubiquitination lead to the formation of poly-Ub chains or multi-monoubiquitination, which direct the substrate to different biological fates such as degradation by the 26S proteasome. RING E3s comprise the largest family of E3s with approximately 600 members in humans. Over the last fifteen years, structural biology and biochemical studies have paved the way for understanding how RING E3s interact with E2s and substrates, and how they are regulated. Recently my group has trapped the crystal structure of a RING E3 bound to an E2 covalently-linked to Ub (E2~Ub), thus providing a molecular snapshot of how RING E3 optimizes E2~Ub for catalysis. Despite these advances, the mechanisms of RING E3-catalyzed ubiquitination are not completely understood. Here, we propose to investigate three key aspects of RING E3 functions. First, we will determine structures of several RING E3s bound to E2~Ub to dissect the molecular basis for RING E3-E2~Ub selectivity. Second, our recent structure of a RING E3, Cbl-b, bound to E2~Ub and a substrate peptide provides a starting point for structural determination of a more challenging RING E3-E2~Ub-intact substrate complex to elucidate the mechanisms of substrate ubiquitination. Third, we have developed an ubiquitinated Cbl-substrate mimetic to study the mechanisms of RING E3-catalyzed poly-ubiquitination using structural and biochemical approaches. Expected results will greatly expand our knowledge of RING E3-mediated ubiquitination and will foster strategies in exploiting E3s for therapeutic development, since deregulation of E3s underlies many diseases including cancers.

Keywords: ubiquitin,e3 ligase,ring e3,protein degradation
Feasibility assessment of a cloud application platform for rational drug design using high throughput molecular dynamics (HTMD)

Framework: Horizon 2020 — Industrial Leadership
Programme: Information and Communication Technologies
Action type: SME instrument
Countries involved: Spain
Call: Open Disruptive Innovation Scheme (implemented through the SME instrument) (H2020-SMEINST-1-2014, 2014)
Start date: 2015-06-01
End date: 2015-11-30
Duration (months): 6.0
Total project cost (EUR): 71429.0
EU funding (EUR): 50000.0
Participants: 1
Project status: CLOSED

The pharmaceutical industry’s increasing spending on R&D is not translating into new and better drugs at the pace required to maintain competitiveness. In-silico computational methods are beginning to gain traction in the progress towards more rational drug discovery workflows. Among the methods available, molecular dynamics (MD) provides the most accurate and useful description of molecular interactions, but the current state of the art has both a high degree of unnecessary technical complexity, and is computationally expensive. Together, these two factors have produced a high barrier to entry that substantially limits research productivity.Acellera looks to address these issues by proposing a cloud application platform for high-throughput MD (HTMD) simulations. This computational platform combines proprietary simulation technology - optimized for speed and simulation throughput – and user-friendly interfaces in a cloud environment to provide a novel resource for drug candidate identification. HTMD, which allows understanding with an unprecedented degree of resolution and accuracy how drugs interact with their biological targets, can significantly reduce the cost of pre-clinical research (PCR) by virtualizing key steps. It is currently estimated that pharmaceutical companies invest approximately 1000M Euro per approved drug. As a global leader in the development of technology for high-throughput molecular dynamics, Acellera is uniquely positioned to bring this disruptive computational technology to the market. The HTMD platform is ready for prototyping in an operational environment (TRL 6). Acellera proposes a Phase 1 SME Instrument to support the execution of a feasibility study into the market viability of the HTMD solution for pre-clinical research. Results of the study will be used to inform preparations for a larger-scale demonstration in Phase 2 and for the subsequent market launch.

Keywords: in silico drug design,simulation,cloud application platform
Demonstration of solvent and resin production from lignocellulosic biomass via the platform chemical levulinic acid (GreenSolRes)

Framework: Horizon 2020 — Societal Challenges
Programme: Food security, sustainable agriculture and forestry, marine and maritime and inland water research and the bioeconomy
Theme: Public-private partnerships
Destination: Bio-based Industries
Action type: Innovation actions
Partnership: BBI (Art-187)
Countries involved: Austria,Germany,Germany,Germany,Germany,Italy,Germany,Belgium,Netherlands,Netherlands
Call: Lignocellulosic feedstocks into chemical building blocks and high added value products (H2020-BBI-PPP-2015-2-1, 2015)
Start date: 2016-09-01
End date: 2021-12-31
Duration (months): 64.0
Total project cost (EUR): 8938806.71
EU funding (EUR): 7451945.62
Participants: 11
Project status: CLOSED

The GreenSolRes project demonstrates the levulinic acid (LVA) value chain of lignocellulosic feedstocks to high-value products in a 3-step approach on TRL 6. First, a demonstration plant in Biorefinery of RWTH Aachen will be designed and build for conversion of lignocellulosic biomass to the platform chemical levulinic acid. Levulinic acid hydrolysate separation enables more efficient and purer levulinic acid production. In a 2nd step the versatile platform chemical levulinic acid is hydrogenated to 2-methyltetrathydrofuran (2-MTHF), gamma-valerolactone (GVL) and 1-methyl-1,4-butanediol (MeBDO) in a direct process developed by RWTH Aachen. These can be produced in the same reactor with a single catalyst by tuning the process conditions. In parallel, BASF will investigate the conversion of LVA esters to MeBDO and GVL. Third, the application of the products as solvents is validated in adhesives and the pharma sector as substitute of their less sustainable C4-analogues. Additionally, HENKEL studies the development of respective new polymers with improved properties. The basic engineering of first commercial plants for these steps supports rapid upscaling and exploitation after the project. This will release these products from the niche markets they are confined to due to ineffective existing production routes. At competitive prices compared to their petrochemical C4-counterparts these chemicals and related products will boost the bio-based market as they have a high greenhouse gas emission avoidance of at least 70% and an additional value to society via better health & safety properties. The whole value chain from e.g. forestry residues to consumer products is assessed for environmental sustainability, risks and health & safety to support business case development and market implementation.

Keywords: green solvents,green adhesives,levulinic acid,multi stage hydrogenation demo,homogeneous catalysis
Does Cross-border Cooperation relate to a Humanist-ETHical cOde of valueS? Theorizing the institutionalization of a cross-border governance humanist ethical code. (CBC-ETHOS)

Framework: Horizon 2020 — Excellent Science
Programme: Marie-Sklodowska-Curie Actions
Theme: Marie Skłodowska-Curie
Destination: Individual Fellowships (IF)-Standard European Fellowships
Action type: Marie Skłodowska-Curie actions
Panel: Social Sciences and Humanities
Countries involved: France
Call: Individual Fellowships (H2020-MSCA-IF-2017, 2017)
Start date: 2018-09-01
End date: 2020-12-01
Duration (months): 24.0
Total project cost (EUR): 173076.0
EU funding (EUR): 173076.0
Participants: 2
Project status: CLOSED

Is there an ethical dimension in cross-border cooperation (CBC)? How and to what extent are peoples’ lives affected by CBC and what is the role people play in shaping the CBC social order? What are the ethical values promoted by the European Union (EU) through CBC? Although European Union border scholars and practitioners highlight how important is to consider the ethical dimension of CBC for its successful management, this dimension has been so far neglected and understudied because of the lack of an appropriate methodological and theoretical background. Thus, I aim first, to fill this academic and policy making gap by addressing these questions and by proposing a pioneering ethical-humanist approach to CBC; second, to empirically test the cross-border governance ethical code that I have recently started elaborating. I argue that the ethical dimension of CBC needs to be scrutinized since border spaces are part and parcel of human activities and precisely because they are ‘human’, they must be structured and governed in an ethical manner. And the CBG ethical-code elaborated here is the necessary lynchpin to boost/strengthen integration. It is normatively important to institutionally determine whether ethical values such as trust, obligations, responsibility, solidarity and gift on which social exchange is grounded are considered by policy makers and stakeholders operating on CBC policies. The outcome of this analysis is an original, alternative modern CBC roadmap that promotes social conditions through which human beings as well as their natural environment can harmoniously develop through the fulfillment of specific needs. Finally, through CBC-ETHOS I will show ‘how’ and ‘to what extent’ multi-scalar (private and public) (non)government levels change themselves in their ‘normative’ institutional make-up and outlooks due to CBC.

Keywords: eu cross border cooperation,cross border governance ethical code of values,cross border regions,cross border regionalism,new regionalism approach,european grouping of territorial cooperation
HIGH QUALITY AND COST-EFFECTIVE METAL AM POWDER FOR MANUFACTURING LOWER WEIGHT COMPONENTS WITH IMPROVED PROPERTIES FOR AIRCRAFT AND AUTOMOBILES (Innopowder)

Framework: Horizon 2020 — Industrial Leadership
Programme: Innovation in SMEs
Action type: SME instrument
Countries involved: Spain
Call: SME instrument (H2020-SMEInst-2018-2020-2, 2018)
Start date: 2018-05-01
End date: 2021-12-31
Duration (months): 44.0
Total project cost (EUR): 2095763.75
EU funding (EUR): 1467034.63
Participants: 1
Project status: CLOSED

3D Printing, or Additive Manufacturing (AM) is a disruptive technology that produces light, high strength components (allowing a weight reduction of 40–60% in the engines, turbines, turbochargers, and structural parts) and novel complex geometries. In addition, 3D printing does not require tools, which means that component manufacturers consume less energy and raw materials. The problem is that raw materials used in 3D printers are conventional materials that have been adapted for 3D printing and they lack the specific technical properties required for aircraft and automobile components, and are also very expensive. Despite the potential benefits of 3D printing, the result is that the 3D printing production costs are prohibitively high in comparison to conventional methods, while the quality of the final components is worse. Innomaq21 SL is a Spanish SME that has designed an atomiser that uses a new technology that produces high-quality metal powders at lower cost. Therefore, INNOPOWDER is a high-quality and cost-effective metal powder for manufacturing transport components through 3D printers. INNOPOWDER has been designed and optimised by our material engineers and it has superior characteristics compared to the currently commercially available metal powders. Innomaq21 aims to use the SME instrument to scale up the production of INNOPOWDER and bring it to the transport market, achieving total profits of over 16M€ by 2024 and providing 36 new jobs.

Keywords: metal powder,3d printing,additive manufacturing,reduce production cost,increase security of vehicles,reduce fuel consumption,reduce emissions
A Multi-Criteria Decision Support System For A Common Forest Management to Strengthen Forest Resilience, Harmonise Stakeholder Interests and Ensure Sustainable Wood Flows (ONEforest)

Framework: Horizon 2020 — Societal Challenges
Programme: Food security, sustainable agriculture and forestry, marine and maritime and inland water research and the bioeconomy
Theme: Sustainable agriculture and forestry
Action type: Research and Innovation actions
Countries involved: Germany,Germany,Italy,Austria,Germany,Germany,Germany,Estonia,Italy,Italy,Spain,Spain,Germany,Slovenia,Sweden,Switzerland
Call: Sustainable wood value chains (H2020-RUR-2020-2, 2020)
Start date: 2021-06-01
End date: 2024-05-31
Duration (months): 36.0
Total project cost (EUR): 5241423.75
EU funding (EUR): 5213205.0
Participants: 20
Project status: SIGNED

Forest ecosystems cover 42 % of the European Union’s total land area and strong efforts have been made to facilitate an increase of multiple forest ecosystem services to form robust forest stands. However, all ecosystems recently have been hit by rapidly changing climatic conditions, e.g. long lasting droughts, heavy rain events, frequent and intensive storms, pests and forest fires. To address this within future silviculture management concepts, forest operations and wood supply, all stakeholders along the Forest Wood Value Chain will need to form a common idea of future forest management, while none of them can increase its benefit without harming another one. Therefore, four Case Studies Regions will be established, following Europe’s biogeographical regions, to study climate-resilient silvicultural management practices and new methods of seeding and planting by the application of an own engineered topsoil cover based on wood fibres. Corresponding forest operations and concepts of actions in case of disturbances will be developed under selected sustainability criteria. Stakeholders will be activated in the participative process of socio-economic studies. The information will be consolidated in Dynamic Value Chain Model to assess the impact of the Forest-Wood Value Chain on regional development quantified by a set of economic, environmental and social indicators. The newly developed Multi-Criteria Decision Support System visualises decision-making by comparing Sustainable Forest Management, synergies and trade-offs of Forest Ecosystems, reliable wood supply, and stakeholder interests through FWVC indicators of social, economic, and environmental dimensions, by applying methods of Goal Programming. The easy-to-use software application will be available for Forest-Wood Value Chain stakeholders globally. All ONEforest results will be implemented in new Model Forests, being part of the International Model Forest Network for regional adapted forest management concept.

Keywords: stakeholder interest,stakeholder participation,dynamic value chain,material flow analysis,multi criteria decision support system,silvicultural management concept
Bioinformatics Services for Data-Driven Design of Cell Factories and Communities (DD-DeCaF)

Framework: Horizon 2020 — Industrial Leadership
Programme: Nanotechnologies, Advanced Materials, Advanced Manufacturing and Processing, and Biotechnology
Theme: Biotechnology
Action type: Research and Innovation actions
Countries involved: Spain,Germany,Switzerland,Sweden,Slovenia,Netherlands,Portugal,Denmark,Denmark
Call: New bioinformatics approaches in service of biotechnology (H2020-LEIT-BIO-2015-1, 2015)
Start date: 2016-03-01
End date: 2020-02-29
Duration (months): 48.0
Total project cost (EUR): 7091021.25
EU funding (EUR): 6250636.25
Participants: 11
Project status: CLOSED

Omics data is not leveraged effectively in the biotechnology industry due to lack of tools to rapidly access public and private data and to design cellular manipulations or interventions based on the data. With this project we aim to make a broad spectrum of omics data useful to the biotechnology industry covering application areas ranging from industrial biotechnology to human health. We will develop novel approaches for integrative model-based omics data analysis to enable 1) Identification of novel enzymes and pathways by mining metagenomic data, 2) Data-driven design of cell factories for the production of chemicals and proteins, and 3) Analysis and design of microbial communities relevant to human health, industrial biotechnology and agriculture. All research efforts will be integrated in an interactive web-based platform that will be available for the industrial and academic research and development communities, in particular enhancing the competitiveness of biotech SMEs by economizing resources and reducing time-to-market within their respective focus areas. The platform will be composed of standardized and interoperable components that service-oriented bioinformatics SMEs involved in the project can reuse in their own products. An important aspect of the platform will be implementation of different access levels to data and software tools allowing controlling access to proprietary data and analysis tools. Two end-user companies will be involved in practical testing of the platform built within the project using proprietary omics data generated at the companies.

Keywords: cell factories,microbial communities,synthetic biology,systems biology
4D Printing of Human Vascularized Cardiac Patches and Hearts for Regenerative Medicine (4DPrintedHeart)

Framework: Horizon 2020 — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Consolidator grants
Action type: ERC actions
Panel: Prevention, Diagnosis and Treatment of Human Diseases
Panel description: Medical technologies and tools for prevention, diagnosis and treatment of human diseases, therapeutic approaches and interventions, pharmacology, preventative medicine, epidemiology and public health, digital medicine
Countries involved: Israel
Call: ERC CONSOLIDATOR GRANTS (ERC-2020-COG, 2020)
Start date: 2021-07-01
End date: 2026-06-30
Duration (months): 60.0
Total project cost (EUR): 2000000.0
EU funding (EUR): 2000000.0
Participants: 1
Project status: SIGNED

Heart diseases are a major cause of death in the Western world. No sustainable regenerative therapy is currently available, and cardiac transplantation is the only treatment. However, the scarcity of matching heart donors raises the need to develop new regenerative medicine approaches. Recently, our group has shown the use of patient-specific cells and personalized hydrogels to 3D print vascularized cardiac patches. Moreover, we have developed printing technologies which allowed to print small-scale, cellularized human hearts with the major blood vessels. Despite these and other advances in the field, the premature hearts are very basic, and their ability to pump blood and function in vivo is still considered futuristic, requiring several major breakthroughs. In this proposal, I plan to go far beyond the current state-of-the-art and overcome some of the remaining challenges in the field. We will develop novel 4D printing approaches, allowing to print human cardiac patches and whole functional hearts, including ventricles, atria, pacemakers, conduction system and extensive vasculature, in high resolution. We will decipher the mechanisms underlying the maturation of the printed tissues and hearts, which are essential for the synchronous contraction and heart pumping. Functionality of the printed structures will be compared to that of native cardiac tissues and whole natural hearts by examining their reaction to chronotropic and cardiotoxic drugs, proving their additional potential to serve as reliable, predictive drug testing platforms. The printed tissues and hearts will be then heterotopically transplanted, and their anastomosis with the host blood vessels, contraction and blood pumping capabilities in vivo will be tested. Finally, we will demonstrate the ability of the printed, vascularized cardiac patches to improve heart function. Successful completion of this ambitious project will provide a sustainable regenerative therapy for a myriad of devastating maladies.

Keywords: regenerative medicine,3d printing of tissues,cell therapy,biomaterials